Global Amikacin API Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Amikacin API Market Insights, Forecast to 2034
Global Amikacin API market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2024 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Amikacin API industry is evaluated to reach US$ million in 2034. The CAGR will be % during 2023 to 2034.
Globally, Amikacin API key manufacturers include Wellona Pharma, VEA Impex, Qilu Pharma, Zhejiang Jinhua Conba, Zhejiang Yongning Pharma, Sichuan Renan Pharma, Chongqing Daxin Pharma and Jiangsu Wuzhong Pharma, etc. Wellona Pharma, VEA Impex, Qilu Pharma are top 3 players and held % sales share in total in 2024.
When considering the consumption regions, % volume of Amikacin API were sold to North America, Europe and Asia Pacific in 2024. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2034 and the sales share will be % in 2034. Moreover, China, plays a key role in the whole Amikacin API market and estimated to attract more attentions from industry insiders and investors.
Amikacin API can be divided into Amikacin and Amikacin Sulfate, etc. Amikacin is the mainstream product in the market, accounting for % sales share globally in 2024 and the proportion will be % in 2034.
Amikacin API is widely used in various fields, such as Injection and Oral, etc. Injection provides greatest supports to the Amikacin API industry development. In 2024, global % sales of Amikacin API went into Injection filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global Amikacin API market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Amikacin API market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2023 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

Wellona Pharma
VEA Impex
Qilu Pharma
Zhejiang Jinhua Conba
Zhejiang Yongning Pharma
Sichuan Renan Pharma
Chongqing Daxin Pharma
Jiangsu Wuzhong Pharma
Segment by Type
Amikacin
Amikacin Sulfate
Injection
Oral
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Amikacin API plant distribution, commercial date of Amikacin API, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Amikacin API introduction, etc. Amikacin API Sales, Revenue, Price and Gross Margin of each company from 2018 to 2023
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Amikacin API
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Globally, Amikacin API key manufacturers include Wellona Pharma, VEA Impex, Qilu Pharma, Zhejiang Jinhua Conba, Zhejiang Yongning Pharma, Sichuan Renan Pharma, Chongqing Daxin Pharma and Jiangsu Wuzhong Pharma, etc. Wellona Pharma, VEA Impex, Qilu Pharma are top 3 players and held % sales share in total in 2024.
When considering the consumption regions, % volume of Amikacin API were sold to North America, Europe and Asia Pacific in 2024. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2034 and the sales share will be % in 2034. Moreover, China, plays a key role in the whole Amikacin API market and estimated to attract more attentions from industry insiders and investors.
Amikacin API can be divided into Amikacin and Amikacin Sulfate, etc. Amikacin is the mainstream product in the market, accounting for % sales share globally in 2024 and the proportion will be % in 2034.
Amikacin API is widely used in various fields, such as Injection and Oral, etc. Injection provides greatest supports to the Amikacin API industry development. In 2024, global % sales of Amikacin API went into Injection filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global Amikacin API market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Amikacin API market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2023 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

By Company
Wellona Pharma
VEA Impex
Qilu Pharma
Zhejiang Jinhua Conba
Zhejiang Yongning Pharma
Sichuan Renan Pharma
Chongqing Daxin Pharma
Jiangsu Wuzhong Pharma
Segment by Type
Amikacin
Amikacin Sulfate
Segment by Application
Injection
Oral
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Amikacin API plant distribution, commercial date of Amikacin API, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Amikacin API introduction, etc. Amikacin API Sales, Revenue, Price and Gross Margin of each company from 2018 to 2023
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Amikacin API
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
